GSK Commits $30 Billion To U.S. Expansion Over Five Years

GSK GSK is making a massive bet on the U.S., saying it will invest at least $30 billion over the next five years to grow its research and supply chain footprint. The announcement came as President Donald Trump arrived in the U.K. for his second state visit.

The plan includes a new $1.2 billion investment in advanced manufacturing from AI and digital upgrades at existing plants to a brand-new factory in Upper Merion, Pennsylvania. That site, set to break ground in 2026, will focus on medicines for respiratory illnesses and cancer.

The British drugmaker also plans to expand drug substance production and improve device and auto-injector assembly. New facilities will bridge R&D and manufacturing across both the U.S. and U.K., strengthening the two countries' leadership in life sciences, GSK said.

The U.S. is expected to become GSK's biggest hub for trials over the next five years. The company has already spent about $2 billion on U.S. manufacturing in the past year even as Trump has pressed pharma companies to boost domestic output with the threat of tariffs.